The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase  by Au, T.K et al.
The plant ribosome inactivating proteins lu⁄n and saporin are potent
inhibitors of HIV-1 integrase
T.K. Au, R.A. Collins, T.L. Lam, T.B. Ng, W.P. Fong, D.C.C. Wan*
Department of Biochemistry, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
Received 31 January 2000; received in revised form 13 March 2000
Edited by Pierre Jolles
Abstract The ribosome inactivating proteins (RIPs) are a
group of proteins that are able to inactivate eukaryotic protein
synthesis by attacking the 28S ribosomal RNA. Recent studies
have shown that some RIPs possess strong anti-human
immunodeficiency virus (HIV) activity. In this study, several
common plant RIPs including agrostin, gelonin, luffin,
K-momorcharin, L-momorcharin, saporin and trichosanthin were
examined for the ability to interfere with HIV-1 replication in a
variety of mechanistic assays in vitro. These assays included the
CD4/gp120 interaction assay, HIV-1 reverse transcriptase (RT)
assay, HIV-1 protease assay and HIV-1 integrase assay. At the
concentration of 100 nM, all RIPs appeared to enhance the CD4/
gp120 interaction by about 50%. These RIPs exhibited a very
weak suppressive effect on HIV-1 RT and on HIV-1 protease. In
contrast, with the exception of agrostin, all the RIPs tested could
strongly inhibit HIV-1 integrase, the extent of inhibition ranging
from 26.1 to 96.3% in an ELISA-based assay. Two RIPs,
saporin and luffin, which licited over 90% inhibition in the
ELISA-based assay, were further characterized in a radiometric
assay. Both of these two RIPs evoked a strong dose-dependent
inhibition in the 3P-end processing and strand-transfer activities
of integrase. The results from this study suggest that the anti-
HIV property of RIPs may be due to inhibition of HIV-1
integrase.
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1. Introduction
Ribosome inactivating proteins (RIPs) are proteins that
speci¢cally interfere with eukaryotic protein translation.
Most plant and bacterial RIPs exert their e¡ects through
binding to the large 60S ribosomal subunit on which they
act as N-glycosidases; speci¢cally cleaving the adenine base
A-4324 from its ribose moiety in the 28S ribosomal RNA
subunit. This results in the inability of the ribosome to bind
elongation factor 2 and thus terminating translation [1]. RIPs
are widely distributed in nature but are found predominantly
in plants, bacteria and fungi. They vary greatly in their phys-
ical properties and cellular e¡ects [2,3]. Many of the plants
from which RIPs are isolated are used medicinally in tradi-
tional Chinese medicine and the RIPs may account for some
of the reported clinical e⁄cacy. These proteins display a
myriad of pharmacological properties comprising anti-viral,
anti-tumor, immunosuppressive, embryotoxic, anti-fertility
[4,5] and enzymatic activities [6].
McGrath et al. [7,8] and Yeung [9] were the ¢rst to docu-
ment that RIPs including trichosanthin, K-momorcharin and
L-momorcharin inhibited human immunode¢ciency virus
(HIV) replication in acutely and chronically infected cells of
lymphocyte and mononuclear phagocyte lineage. Ferrari et al.
[10] reported that trichosanthin inhibited HIV replication in
H9 and CEM-SS cells, and syncytium formation between in-
fected H9 cells and uninfected Sup-T1 cells. Lee-Huang et al.
[11,12] detailed the isolation of anti-HIV proteins, which they
coined MAP30 and TAP29, respectively, from Momordica
charantia seeds and Trichosanthes kirilowii tubers, the same
tissues used for preparing momorcharins and trichosanthin.
Both MAP30 and TAP29 elicited a dose-dependent inhibition
of cell-free HIV-1 infection and replication. Viral-associated
reverse transcriptase (RT) activity in HIV-1-infected H9 cells
was also inhibited in conjunction with a suppression of syn-
cytium formation in the CD4-positive, syncytium-sensitive,
Leu3a-sensitive T cell line CEM-SS and viral core protein
p24 expression. Later, they demonstrated that MAP30 and
GAP31 (from Gelonium multi£orum) could inhibit HIV-1 in-
tegrase with an EC50 of 1 WM [13]. Here, we report our work
to determine whether RIPs from certain plants were endowed
with the ability to inhibit replication of HIV-1 in a series of in
vitro mechanistic assays.
2. Materials and methods
2.1. RIPs
The RIPs agrostin, gelonin, lu⁄n and saporin were purchased from
Sigma Chemical Co., St. Louis, MO, USA. K-Momorcharin, L-mo-
morcharin and trichosanthin were puri¢ed in-house as detailed in [4].
All RIPs were dissolved in phosphate-bu¡ered saline (PBS) and stored
at 320‡C until use.
2.2. Assay for cell-free translation inhibitory activity
In the protein synthesis assay [14], the reticulocyte mix and hot mix
were prepared as follows. The reticulocyte mix contained rabbit retic-
ulocyte lysate, creatine kinase (5 mg/ml), hemin (0.65 mg/ml) and
water in the ratio of 60:4:10:40 (v/v). The hot mix contained creatine
phosphate (0.4 M), KCl/MgCl2 (1 M/10 mM) and [3H]leucine
(0.25 mCi) in the ratio of 4:7:1. The assay mix contained the retic-
ulocyte mix, hot mix and test sample (1 mg/ml) in the ratio of
30:10:10. The assay mix was incubated at 30‡C for 30 min. The
reaction was stopped by the addition of NaOH and H2O2 and incu-
bation at 37‡C for 10 min to digest amino-acyl tRNA and decolorize
the solution. Trichloroacetic acid (40%), containing 0.2% casein hy-
drolysate, was added followed by incubation on ice for 10 min to
precipitate [3H]leucine-labelled proteins. The precipitate was ¢ltered
through a glass ¢ber ¢lter, washed with ethanol and dried under
vacuum. The ¢lter was submerged in scintillation £uid and radioac-
tivity was counted.
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2.3. CD4/gp120 interaction assay
Inhibition of the interaction between immobilized recombinant
CD4 and recombinant HIV-1 gp120 was determined with a commer-
cially available enzyme immunoassay kit (NEN DuPont, Bedford,
MA, USA).
2.4. RT assay
Inhibition of recombinant HIV-1 RT activity was determined with a
commercially available ELISA kit (Boehringer Mannheim, Germany).
2.5. Expression and puri¢cation of recombinant HIV-1 protease
The expression clone for recombinant human HIV-1 protease was a
generous gift from Dr. J.N. Tang (Oklahoma Medical Research
Foundation, USA). HIV-1 protease cDNA was cloned in pET3b
and transformed into Escherichia coli BL21(DE3)pLysS. HIV-1 pro-
tease expression was induced by IPTG. The expressed proteins, which
were found predominantly as inclusion bodies, were analyzed by so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE). The bacterial colony which expressed a high level of the
11 kDa HIV-1 protease was picked and chosen for preparation of
large-scale cultures. The procedure for puri¢cation of HIV-1 protease
from cultures was carried out as described in [15].
2.6. Fluorometric method for HIV-1 protease assay
The activity of HIV-1 protease was assayed by cleavage of a £uo-
rogenic substrate, Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-
Gln-Lys(DABCYL)-Arg (Molecular Probes, USA), in a microtiter
plate format for rapid screening of activity [16]. Brie£y, 6.5 Wg
HIV-1 protease was added to a total of 200 Wl reaction bu¡er
(0.1 M sodium acetate, 1 M NaCl, 1 mM EDTA, 1 mM dithiothreitol,
10% dimethyl sulfoxide, 1 mg/ml bovine serum albumin (BSA),
pH 4.7) containing 10 WM substrate in the presence or absence of
RIPs. After incubation at 37‡C for 2 h, the £uorescence intensity in
each well was measured using a Cyto£uor 2350 £uorescence plate
reader (Millipore Corp., USA) with an excitation wavelength at
340 nm and an emission wavelength at 490 nm.
2.7. Expression and puri¢cation of recombinant HIV-1 integrase
The plasmid that expressed His-tagged wild-type HIV-1 integrase,
pT7-7-His(TX)-HIV-1-IN, was a gift from Dr. S.A. Chow (School of
Medicine, UCLA). To express the protein, a 1 l culture of E. coli
BL21(DE3) cells containing the expression plasmid was grown at
37‡C until OD600 reached 0.7^0.8. Cells were induced by addition of
0.8 mM IPTG and harvested after a 4 h incubation by centrifugation
at 6000Ug for 10 min at 4‡C. Cells were suspended at a concentration
of 10 ml/g wet cell paste in 20 mM Tris^HCl (pH 8.0), containing
0.1 mM EDTA, 2 mM L-mercaptoethanol, 0.5 M NaCl and 5 mM
imidazole. Lysozyme was added to a concentration of 0.2 mg/ml.
After 1 h incubation at 4‡C, the lysate was sonicated and centrifuged
at 40 000Ug at 4‡C for 20 min. The pellet was homogenized in 50 ml
bu¡er A (20 mM Tris^HCl, pH 8.0, 2 M NaCl, 2 mM L-mercapto-
ethanol) containing 5 mM imidazole. The suspension was rotated at
4‡C for 1 h and cleared by centrifugation at 40 000Ug at 4‡C for
20 min. The supernatant was loaded onto a 1 ml chelating Sepharose
column charged with 50 mM NiSO4 and was equilibrated with bu¡er
A containing 5 mM imidazole. The column was washed with ¢ve
column volumes of bu¡er A containing 5 mM imidazole and the
protein was eluted with three column volumes of bu¡er A containing
200 mM and 400 mM imidazole, respectively. Protein-containing frac-
tions were pooled and EDTA was added to a ¢nal concentration of
5 mM. The protein was dialyzed against bu¡er B (20 mM HEPES, pH
7.5, 1 mM EDTA, 1 M NaCl, 20% glycerol) containing 2 mM L-mer-
captoethanol and then against bu¡er B containing 1 mM dithiothrei-
tol. Aliquots of the protein were stored at 370‡C.
2.8. HIV-1 integrase assays
A non-radioactive ELISA-based HIV-1 integrase assay was per-
formed according to the DNA-coated plates method as detailed by
Chang et al. [17] with some modi¢cations. In this study, 1 Wg of SmaI-
linearized pBluescript SK was coated onto each well in the presence of
2 M NaCl as target DNA. The donor DNA was prepared by anneal-
ing VU5BR (5P-biotin-GTGTGGAAAATCTCTAGCAGT-3P) and
VU5 (5P-ACTGCTAGAGATTTTCCACAC-3P) in 10 mM Tris^
HCl, pH 8.0, 1 mM EDTA and 0.1 M NaCl at 80‡C followed by
30 min at room temperature. Integrase reaction was performed in
20 mM HEPES (pH 7.5), containing 10 mM MnCl2, 30 mM NaCl,
10 mM dithiothreitol and 0.05% Nonidet-P40 (Sigma). After the in-
tegrase reaction, the biotinylated DNA immobilized on the wells was
detected by incubation with streptavidin-conjugated alkaline phospha-
tase (Boehringer Mannheim) followed by colorimetric detection with
1 mg/ml p-nitrophenyl phosphate in 10% diethanolamine bu¡er, pH
9.8, containing 0.5 mM MgCl2. The absorbance due to the alkaline
phosphatase reaction was measured at 415 nm.
The radioactive assays for 3P-end processing and strand-transfer
reactions of HIV-1 integrase were performed according to the meth-
ods of Chow [18].
3. Results and discussion
The purpose of this work was to determine the suitability of
using RIPs as inhibitors of HIV-1 replication. There are many
points in the virus life-cycle that can be targeted by potential
therapeutic compounds [19]. In the present study, a variety of
mechanistic assays based on di¡erent therapeutic targets were
used to determine the locus of any inhibitory e¡ect produced
by the various RIPs. The ribosome inactivating activities of
the various RIPs were assessed, prior to assaying their HIV-1
inhibitory properties, by determining their activity in a stan-
dard protein synthesis assay using a rabbit reticulocyte lysate.
As shown in Table 1, at a concentration of 80 nM, all the
RIPs tested could inhibit protein synthesis by 81^100%, indi-
cating that the proteins were biologically active. The RIPs
were also analyzed by SDS^PAGE. All proteins appeared to
be homogeneous and had the expected molecular weights as
estimated from molecular weight markers (data not shown).
The e¡ect of the RIPs on the potential interaction of HIV-1
Fig. 1. Concentration^response curves for inhibition of HIV-1 inte-
grase by lu⁄n (F) and saporin (b). The data were derived from an
ELISA-based integrase assay as described in Section 2. Each data
point represents a mean of three separate measurements. The verti-
cal bars indicate the standard deviations. In the assay, each well of
the DNA-coated plate was supplied with 50 Wl solution containing
20 mM HEPES, pH 7.5, 10 mM MnCl2, 30 mM NaCl, 10 mM di-
thiothreitol, 0.05% Nonidet-P40, 10% DMSO, 0.44 WM integrase,
0.24 WM biotin-labelled donor DNA and di¡erent concentrations of
RIPs. The reaction mixtures were incubated at 37‡C for 1 h. The
wells were then washed with distilled water and 100 Wl of streptavi-
din-conjugated alkaline phosphatase at 1.5 U/ml in 1% BSA and
1UPBS was added to each well. After incubation at room tempera-
ture for 1 h, the wells were washed with distilled water and devel-
oped with p-nitrophenyl phosphate. Absorbance reading at 415 nm
minus the background (reaction in the absence of integrase) repre-
sents the activity due to integrase. The percentage of inhibition was
calculated as: (A3B)/AU100%, where A and B are the absorbance
readings at 415 nm in the absence and presence of RIPs, respec-
tively.
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and its target cell was investigated using an HIV-1 gp120/
immobilized CD4 receptor EIA. At a concentration of 100
nM, all RIPs appeared to enhance the interaction by about
50% (Table 2). This enhancement may be attributed to a
cross-linking of gp120 molecules due to the lectin-like a⁄nity
of the RIPs for carbohydrate groups leading to an enhanced
enzyme signal.
The e¡ects of the RIPs on HIV-1 RT, protease and inte-
grase were studied. As shown in Table 2, the RIPs tested were
only weak inhibitors of RT even when present at 133 nM. The
most potent was lu⁄n which inhibited RT by 27%. Lee-
Huang et al. [11] reported that, at the concentration of 0.33
nM, MAP30 could decrease virus-associated RT activity by
50% in HIV-1-infected H9 cells. However, the inhibition was
most likely due to a decrease in HIV number rather than a
direct inhibition of HIV-1 RT. Similar to RT, the RIPs tested
were only weak inhibitors of HIV-1 protease; only about 10%
of inhibition could be attained at a concentration of 2 WM.
Huang et al. [20] have recently shown that two RIPs, MAP30
and GAP31, were resistant to proteolytic digestion. At 10%
(w/w) protease, only the N- and C-termini were accessible.
The puri¢ed proteolytic fragments of these two RIPs re-
mained fully active in the anti-HIV assay. Therefore, the
lack of inhibition in this study was unlikely due to the diges-
tion of RIPs by HIV-1 protease in the reaction mixtures. For
HIV-1 integrase, with the exception of agrostin, which did not
show any inhibition, all RIPs tested at 5 WM could inhibit
HIV-1 integrase by 26^96%. The most potent were lu⁄n
and saporin, which inhibited integrase by more than 90% in
the ELISA-based assay. Gelonin, L-momorcharin and tricho-
santhin inhibited integrase by 50^68% while K-momorcharin
elicited only 26% inhibition. The response curves for lu⁄n
and saporin on integrase inhibition are shown in Fig. 1.
Both RIPs were nearly equipotent in inhibiting HIV-1 inte-
grase, the concentrations required for 50% inhibition being
Table 1
E¡ects of RIPs on protein synthesis in a rabbit reticulocyte lysate
system
RIP Inhibition (%)
Agrostin 81.6 þ 1.0
Gelonin N.D.
Lu⁄n 93.0 þ 2.8
K-Momorcharin 95.8 þ 5.4
L-Momorcharin 100 þ 0.0
Saporin 91.5 þ 2.5
Trichosanthin 81.3 þ 4.3
The concentration of RIPs used in each case was 80 nM. The re-
sults shown were mean þ S.D. (n = 3). N.D.: not determined.
Table 2
E¡ects of RIPs on CD4/gp120 interaction, HIV-1 RT, protease and integrase
RIP Inhibition (%) (enhancement)
CD4/gp120 HIV-1 RT HIV-1 PR HIV-1 IN
Agrostin (47.5 þ 4.0) 24.2 þ 11.2 15.7 þ 9.0 0.9 þ 1.3
Gelonin N.D. N.D. 12.1 þ 0.6 68.9 þ 0.9
Lu⁄n (56.0 þ 1.2) 27.5 þ 2.8 14.0 þ 1.2 96.3 þ 2.0
K-Momorcharin (48.8 þ 5.0) 4.5 þ 2.8 8.5 þ 2.0 26.1 þ 1.5
L-Momorcharin (58.6 þ 5.5) 3.4 þ 0.6 9.0 þ 1.6 50.8 þ 2.4
Saporin (59.7 þ 0.7) (4.5 þ 4.5) 9.1 þ 2.9 94.3 þ 0.3
Trichosanthin (51.4 þ 3.7) (6.2 þ 3.9) 10.1 þ 2.7 69.3 þ 1.7
The concentrations of RIPs used in CD4/gp120 interaction assay, RT assay, protease assay and integrase assay were 100 nM, 133 nM, 2 WM
and 5 WM, respectively. The results shown were mean þ S.D. (n = 3). N.D.: not determined. Data in parentheses represent enhancement while
data without parentheses represent inhibition. RT, PR and IN stand for reverse transcriptase, protease and integrase, respectively.
Fig. 2. Inhibition of HIV-1 integrase-catalyzed 3P-end processing (A)
and strand-transfer (B) by lu⁄n and saporin. The reaction products
were separated by denaturing gel and visualized by autoradiogra-
phy. Lane 1, positive control with integrase. Lane 2, unreacted sub-
strate. Lanes 3^7, reactions in the presence of indicated concentra-
tions of lu⁄n. Lanes 8^12, reactions in the presence of indicated
concentrations of saporin. Reaction was performed in a volume of
20 Wl containing 20 mM HEPES, pH 7.5, 10 mM MnCl2, 30 mM
NaCl, 10 mM dithiothreitol, 0.05% Nonidet-P40, 10% DMSO,
0.3 WM integrase and 50 nM 5P-end 32P-labelled oligonucleotide sub-
strates. The reaction mixtures were incubated at 37‡C for 1 h and
stopped by the addition of 10 Wl of loading bu¡er (98% deionized
formamide, 10 mM EDTA, pH 8.0, and 0.05% bromophenol blue,
0.05% xylene cyanol) followed by heating at 80‡C for 5 min. 5 Wl
from each of the reaction mixtures was used for denaturing gel elec-
trophoresis. S indicates unreacted substrate, TC indicates terminal
processed products and ST indicates strand-transfer products.
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0.25 WM for saporin and 0.53 WM for lu⁄n. These ¢gures
were comparable to the value of 1 WM reported for MAP30
and GAP31 [13]. Integrase acts in two steps: the ¢rst step
processes the linear viral DNA by removing two nucleotides
from each 3P-end, leaving recessed 3P-OH termini. This step is
known as 3P-end processing. The second step, strand-transfer,
is a trans-esteri¢cation of phosphodiester bonds in which a
host DNA strand is cut, and the 5P-end of the cut is joined
to a processed viral 3P-terminus. In order to further character-
ize the mode of inhibition by lu⁄n and saporin, these two
steps were assayed separately using 32P-labelled oligonucleo-
tides of viral terminal sequence in a cell-free system. PAGE in
a 20% denaturing gel allows the separation of reaction prod-
ucts from the substrate [18]. Fig. 2 shows the e¡ects of lu⁄n
and saporin on the 3P-end processing and strand-transfer ac-
tivities of HIV-1 integrase. It was found that both activities
could be inhibited by lu⁄n and saporin in a dose-dependent
manner. The 3P-end processing was assayed using a 21-mer
double-stranded oligonucleotide that mimics the U5 end of
the HIV LTR as substrate. 3P-End processing by integrase
would liberate a GT dinucleotide from the 3P-end, resulting
in the formation of a 19-mer oligonucleotide. As shown in
Fig. 2A, the accumulation of the 19-mer oligonucleotide
cleavage product decreased as the concentrations of RIPs in-
creased. To assay strand-transfer, a 19-mer oligonucleotide
was annealed to a 21-mer oligonucleotide, this 3P-end recessed
substrate mimics the 3P-end processed product and undergoes
strand-transfer reaction only. The strand-transfer reaction
products accumulated as oligonucleotides with slower mobi-
lities in denaturing gel. Lu⁄n and saporin could also inhibit
the strand-transfer activity of HIV-1 integrase in a dose-de-
pendent manner (Fig. 2B). It can be estimated that the con-
centration for 50% inhibition was V30^60 nM for lu⁄n and
V60^130 nM for saporin in both assays as the accumulations
of reaction products were nearly decreased by half in these
concentration ranges.
RIPs are a diverse group of proteins with a wide range of
physical properties and cellular e¡ects. Recent studies have
identi¢ed a number of RIPs with signi¢cant anti-HIV-1 e¡ects
at nanomolar concentrations [11,12,21]. However, the ribo-
some inactivating activity of RIPs may not account for their
anti-HIV activities. For instance, Barbieri et al. [3] showed
that trichosanthin could selectively inhibit HIV RNA and
protein accumulation without a¡ecting host cell gene expres-
sion. Recently, Huang et al. [20] demonstrated that proteolytic
fragments of MAP30 and GAP31 were fully active against
HIV-1 but not in ribosome inactivation. These results sug-
gested that RIPs’ anti-HIV and ribosome inactivating activ-
ities are entirely di¡erent. In this study, the lack of a striking
e¡ect of RIPs on CD4/gp120 interaction, HIV-1 RT and also
HIV-1 protease suggests that the mechanism of anti-HIV ac-
tion of the RIPs does not involve CD4/gp120, HIV RT and
protease. The HIV-1 integrase represents an attractive possi-
bility for the development of anti-HIV drugs because the host
cells do not make or require integrase.
Lee-Huang et al. ¢rst demonstrated that two RIPs, MAP30
and GAP31, possess inhibitory activity on HIV-1 integrase
[13]. More recently, the solution structure of MAP30 was
resolved [22]. The DNA glycosylase/apurinic lyase activity of
MAP30 was identi¢ed and related to its HIV-1 integrase in-
hibitory action. The di¡erential HIV-1 integrase inhibitory
activities of RIPs in this study may be due to their di¡erent
DNA glycosylase/apurinic lyase activities. Whether similar
glycosylase/apurinic lyase activity could be observed in lu⁄n-
and saporin-associated HIV-1 integrase inhibition requires
further investigation. Taken these together, it suggests that
certain members of the RIP family are potent integrase inhib-
itors.
In conclusion, we found two other members of RIPs, lu⁄n
and saporin, that are potent HIV-1 integrase inhibitors. These
¢ndings con¢rm and further extend the notion that the anti-
HIV e¡ects of these RIPs may be attributed to their potent
HIV-1 integrase inhibition.
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